The pharmacogenomics wave does not seem to have hit European shores just yet: Venture capitalists there have a tepid interest in local SNP and pharmacogenomic startups, and companies there anxious about private-equity financing are in for a long, hot summer, most experts agree. It didn t have to be this way. Subscribe. (https://www.snptech.com/subscribe.htmtarget=_blank)